{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:25:27Z","timestamp":1761513927126},"reference-count":35,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,3]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>The management of thymic epithelial tumors is a paradigm of multidisciplinary collaboration. Chemotherapy may be administered as part of curative-intent sequential strategy integrating subsequent surgery or radiotherapy, or as an exclusive treatment if local treatment is not achievable. Recurrences of thymic epithelial tumors should be managed according to the same strategy as newly diagnosed tumors.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>More options have become available for advanced, refractory, and recurrent thymic epithelial tumors, which include cytotoxic agents such as carboplatin\u2013paclitaxel, pemetrexed, and oral etoposide. Angiogenesis targeting is a standard in advanced lines of treatment, after results of a phase II trial with sunitinib were reported. Ongoing studies are assessing the opportunity of targeting the immune-response checkpoint programmed death-1\/programmed death ligand-1, with preliminary promising results whereas safety, with a higher risk of auto-immunity, may represent a concern.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>Overall, a dramatic improvement in our knowledge of the management of thymic tumors has occurred in the past few years, resulting in the development of databases, translational research programmes, and clinical trials. Although access to innovative strategies represents a major challenge, as the rarity of the tumor precludes specific approval of drugs to be obtained, patient-centered initiatives, such as the establishment of dedicated networks, are warranted.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/cco.0000000000000355","type":"journal-article","created":{"date-parts":[[2016,12,25]],"date-time":"2016-12-25T12:24:13Z","timestamp":1482668653000},"page":"112-117","source":"Crossref","is-referenced-by-count":11,"title":["Systemic treatment for thymic malignancies"],"prefix":"10.1097","volume":"29","author":[{"given":"Nicolas","family":"Girard","sequence":"first","affiliation":[{"name":"Department of Respiratory Medicine, National Expert Centre for Thymic Malignancies, H\u00f4pital Louis Pradel, Hospices Civils de Lyon, Lyon"},{"name":"Department of Medical Oncology, Institut Curie"},{"name":"Institut du Thorax Curie-Montsouris, Institut Curie, Institut Mutualiste Montsouris, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claire","family":"Merveilleux du Vignaux","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, National Expert Centre for Thymic Malignancies, H\u00f4pital Louis Pradel, Hospices Civils de Lyon, Lyon"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R2-20230901","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1097\/JTO.0000000000000154","article-title":"ITMIG consensus statement on the use of the WHO histological classification of thymoma and thymic carcinoma: refined definitions, histological criteria, and reporting","volume":"9","author":"Marx","year":"2014","journal-title":"J Thorac Oncol"},{"key":"R3-20230901","doi-asserted-by":"crossref","first-page":"S1710","DOI":"10.1097\/JTO.0b013e31821e8cff","article-title":"The Masaoka\u2013Koga stage classification for thymic malignancies: clarification and definition of terms","volume":"6","author":"Detterbeck","year":"2011","journal-title":"J Thoracic Oncol"},{"key":"R4-20230901","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.1097\/JTO.0000000000000290","article-title":"The IASLC\/ITMIG Thymic Epithelial Tumors Staging Project: proposal for an evidence-based stage classification system for the forthcoming (8th) edition of the TNM classification of malignant tumors","volume":"9","author":"Detterbeck","year":"2014","journal-title":"J Thorac Oncol"},{"issue":"(Suppl 5)","key":"R5-20230901","doi-asserted-by":"crossref","first-page":"v40","DOI":"10.1093\/annonc\/mdv277","article-title":"Thymic epithelial tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Girard","year":"2015","journal-title":"Ann Oncol"},{"key":"R6-20230901","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1093\/ejcts\/ezt649","article-title":"Tumours of the thymus: a cohort study of prognostic factors from the European Society of Thoracic Surgeons database","volume":"46","author":"Ruffini","year":"2014","journal-title":"Eur J Cardiothorac Surg"},{"key":"R7-20230901","doi-asserted-by":"crossref","first-page":"S1749","DOI":"10.1097\/JTO.0b013e31821ea5f7","article-title":"Chemotherapy definitions and policies for thymic malignancies","volume":"6","author":"Girard","year":"2011","journal-title":"J Thorac Oncol"},{"issue":"(Suppl 2)","key":"R8-20230901","doi-asserted-by":"crossref","first-page":"S131","DOI":"10.1097\/JTO.0000000000000298","article-title":"State of the art of genetic alterations in thymic epithelial tumors","volume":"9","author":"Rajan","year":"2014","journal-title":"J Thorac Oncol"},{"key":"R9-20230901","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1586\/era.12.29","article-title":"Chemotherapy and targeted agents for thymic malignancies","volume":"12","author":"Girard","year":"2012","journal-title":"Expert Rev Anticancer Ther"},{"key":"R10-20230901","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1200\/JCO.1997.15.9.3093","article-title":"Cisplatin, doxorubicin, and cyclophosphamide plus thoracic radiation therapy for limited-stage unresectable thymoma: an intergroup trial","volume":"15","author":"Loehrer","year":"1997","journal-title":"J Clin Oncol"},{"key":"R11-20230901","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.jtcvs.2013.08.061","article-title":"Neoadjuvant chemoradiotherapy for locally advanced thymic tumors: a phase II, multi-institutional clinical trial","volume":"147","author":"Korst","year":"2014","journal-title":"J Thorac Cardiovasc Surg"},{"key":"R12-20230901","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/S0003-4975(03)00555-1","article-title":"Therapy for thymic epithelial tumors: a clinical study of 1,320 patients from Japan","volume":"76","author":"Kondo","year":"2003","journal-title":"Ann Thorac Surg"},{"key":"R13-20230901","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1097\/JTO.0000000000000128","article-title":"Thymic carcinoma: a cohort study of patients from the European Society of Thoracic Surgeons database","volume":"9","author":"Ruffini","year":"2014","journal-title":"J Thorac Oncol"},{"key":"R14-20230901","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jtcvs.2014.09.124","article-title":"Thymic carcinoma outcomes and prognosis: results of an international analysis","volume":"149","author":"Ahmad","year":"2015","journal-title":"J Thorac Cardiovasc Surg"},{"key":"R15-20230901","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1093\/icvts\/ivs133","article-title":"Which stages of thymoma benefit from adjuvant chemotherapy post-thymectomy?","volume":"15","author":"Attaran","year":"2012","journal-title":"Interact Cardiovasc Thorac Surg"},{"key":"R16-20230901","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1200\/JCO.1994.12.6.1164","article-title":"Cisplatin plus doxorubicin plus cyclophosphamide in metastatic or recurrent thymoma: final results of an intergroup trial. The Eastern Cooperative Oncology Group, Southwest Oncology Group, and Southeastern Cancer Study Group","volume":"12","author":"Loehrer","year":"1994","journal-title":"J Clin Oncol"},{"key":"R17-20230901","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1200\/JCO.1996.14.3.814","article-title":"Cisplatin and etoposide combination chemotherapy for locally advanced or metastatic thymoma. A phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group","volume":"14","author":"Giaccone","year":"1996","journal-title":"J Clin Oncol"},{"key":"R18-20230901","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1002\/1097-0142(20010601)91:11<2010::AID-CNCR1226>3.0.CO;2-2","article-title":"Combined etoposide, ifosfamide, and cisplatin in the treatment of patients with advanced thymoma and thymic carcinoma: an intergroup trial","volume":"91","author":"Loehrer","year":"2001","journal-title":"Cancer"},{"key":"R19-20230901","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s00432-014-1800-6","article-title":"Key components of chemotherapy for thymic malignancies: a systematic review and pooled analysis for anthracycline-, carboplatin- or cisplatin-based chemotherapy","volume":"141","author":"Okuma","year":"2015","journal-title":"J Cancer Res Clin Oncol"},{"key":"R20-20230901","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1093\/annonc\/mdu541","article-title":"A multicenter phase II study of carboplatin and paclitaxel for advanced thymic carcinoma: WJOG4207L","volume":"26","author":"Hirai","year":"2015","journal-title":"Ann Oncol"},{"key":"R21-20230901","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1200\/JCO.2010.32.9607","article-title":"Phase II study of carboplatin and paclitaxel in advanced thymoma and thymic carcinoma","volume":"29","author":"Lemma","year":"2011","journal-title":"J Clin Oncol"},{"key":"R22-20230901","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.jtho.2015.09.007","article-title":"Are anthracycline-based regimens truly indicated to be the standard chemotherapy regimen for thymic carcinoma?","volume":"11","author":"Hirai","year":"2016","journal-title":"J Thorac Oncol"},{"key":"R23-20230901","doi-asserted-by":"crossref","first-page":"S119","DOI":"10.1097\/JTO.0000000000000296","article-title":"A practical guide from the International Thymic Malignancy Interest Group (ITMIG) regarding the radiographic assessment of treatment response of thymic epithelial tumors using modified RECIST criteria","volume":"9","author":"Benveniste","year":"2014","journal-title":"J Thorac Oncol"},{"key":"R24-20230901","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1097\/JTO.0000000000000378","article-title":"Surgical management of recurrent thymic epithelial tumors: a retrospective analysis based on the Japanese nationwide database","volume":"10","author":"Mizuno","year":"2015","journal-title":"J Thorac Oncol"},{"key":"R25-20230901","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1093\/annonc\/mdp483","article-title":"Preliminary results of phase II study of capecitabine and gemcitabine (CAP-GEM) in patients with metastatic pretreated thymic epithelial tumors (TETs)","volume":"21","author":"Palmieri","year":"2010","journal-title":"Ann Oncol"},{"key":"R26-20230901","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.lungcan.2014.11.006","article-title":"Pemetrexed in patients with thymic malignancies previously treated with chemotherapy","volume":"87","author":"Liang","year":"2015","journal-title":"Lung Cancer"},{"key":"R27-20230901","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.lungcan.2016.06.020","article-title":"Activity and safety of oral etoposide in pretreated patients with metastatic or recurrent thymic epithelial tumors (TET): a single-institution experience","volume":"99","author":"Bluthgen","year":"2016","journal-title":"Lung Cancer"},{"key":"R28-20230901","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1200\/JCO.2004.02.047","article-title":"Octreotide alone or with prednisone in patients with advanced thymoma and thymic carcinoma: an Eastern Cooperative Oncology Group Phase II Trial","volume":"22","author":"Loehrer","year":"2004","journal-title":"J Clin Oncol"},{"key":"R29-20230901","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1097\/JTO.0000000000000370","article-title":"Long-term results after treatment for recurrent thymoma: a multicenter analysis","volume":"9","author":"Sandri","year":"2014","journal-title":"J Thorac Oncol"},{"key":"R30-20230901","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S1470-2045(14)71181-7","article-title":"Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial","volume":"16","author":"Thomas","year":"2015","journal-title":"Lancet Oncol"},{"key":"R31-20230901","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.lungcan.2016.04.024","article-title":"Sunitinib in patients with advanced thymic malignancies: Cohort from the French RYTHMIC network","volume":"97","author":"Remon","year":"2016","journal-title":"Lung Cancer"},{"issue":"(Suppl)","key":"R32-20230901","first-page":"5s","article-title":"Phase II study of everolimus in patients with thymoma and thymic carcinoma previously treated with cisplatin-based chemotherapy","volume":"32","author":"Zucali","year":"2014","journal-title":"J Clin Oncol"},{"key":"R33-20230901","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1016\/j.jtho.2016.04.013","article-title":"PI3K as a potential therapeutic target in thymic epithelial tumors","volume":"11","author":"Alberobello","year":"2016","journal-title":"J Thorac Oncol"},{"key":"R34-20230901","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1016\/j.jtho.2016.06.007","article-title":"Chasing therapeutic targets in thymic malignancies: finding needles in the haystack to frame a comprehensive canvas?","volume":"11","author":"Girard","year":"2016","journal-title":"J Thorac Oncol"},{"issue":"(Suppl)","key":"R35-20230901","article-title":"A phase II study of pembrolizumab in patients with recurrent thymic carcinoma","volume":"34","author":"Giaccone","year":"2016","journal-title":"J Clin Oncol"},{"key":"R36-20230901","first-page":"S523","article-title":"Chemotherapy in advanced thymic epithelial tumors: insights from the RYTHMIC prospective cohort","volume":"12","author":"Merveilleux du VIgnaux","year":"2016","journal-title":"J Thorac Oncol"}],"container-title":["Current Opinion in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00001622-201703000-00005","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T06:17:37Z","timestamp":1693549057000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00001622-201703000-00005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1097\/cco.0000000000000355","relation":{},"ISSN":["1040-8746","1531-703X"],"issn-type":[{"value":"1040-8746","type":"print"},{"value":"1531-703X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3]]}}}